Smart Innovation Platform for Preclinical Drug Development

Booth No: N416

Characteristic

The Smart Innovation Platform for Preclinical Drug Development (Mol Prospector) is an AI-powered platform designed specifically for early-stage small molecule drug discovery. By combining cutting-edge algorithms with deep research expertise, it offers AI drug discovery services, early-stage drug asset licensing, and co-development opportunities for academic institutions, biotech startups, and pharmaceutical companies.

Mol Prospector can design high-potential inhibitors within just 16 days, complete compound synthesis in 2–3 days, and deliver in vitro validated lead compounds within as little as 5 months. Its built-in ADMET prediction tool evaluates compound toxicity in minutes, helping reduce animal test failures and save time and cost.

The platform offers three major advantages:
1. High predictive power with limited data, expanding its use across different research scenarios.
2. Excellent synthetic feasibility, with an 80% synthesis success rate and up to 90% reduction in synthesis costs.
3. Strong experimental validation, with a 50% hit rate in cell-based assays.
These strengths make Mol Prospector a game-changing tool for rapidly designing patentable, effective small molecule drug candidates.